Anti-Smad4 antibody (ab236321)
Key features and details
- Rabbit polyclonal to Smad4
- Suitable for: IP, IHC-P, WB
- Reacts with: Mouse, Human
- Isotype: IgG
Get better batch-to-batch reproducibility with a recombinant antibody
- Research with confidence – consistent and reproducible results with every batch
- Long-term and scalable supply – powered by recombinant technology for fast production
- Success from the first experiment – confirmed specificity through extensive validation
- Ethical standards compliant – production is animal-free
Overview
-
Product name
Anti-Smad4 antibody
See all Smad4 primary antibodies -
Description
Rabbit polyclonal to Smad4 -
Host species
Rabbit -
Tested applications
Suitable for: IP, IHC-P, WBmore details -
Species reactivity
Reacts with: Mouse, Human
Predicted to work with: Rat, Cow, Pig -
Immunogen
Recombinant fragment corresponding to Human Smad4 aa 1-200.
Database link: Q13485 -
Positive control
- WB: SH-SY5Y, 3T3 and HepG2 whole cell lysate. IHC-P: Human colon cancer and kidney tissue. IP: Jurkat cells.
-
General notes
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.40
Preservative: 0.03% Proclin 300
Constituents: PBS, 50% Glycerol (glycerin, glycerine) -
Concentration information loading...
-
Purity
Protein G purified -
Purification notes
Protein >95%. -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
-
Positive Controls
-
Recombinant Protein
-
Related Products
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab236321 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
IP |
1/200 - 1/2000.
|
|
IHC-P |
1/20 - 1/200.
|
|
WB |
1/500 - 1/2000. Predicted molecular weight: 60 kDa.
|
Notes |
---|
IP
1/200 - 1/2000. |
IHC-P
1/20 - 1/200. |
WB
1/500 - 1/2000. Predicted molecular weight: 60 kDa. |
Target
-
Function
Common SMAD (co-SMAD) is the coactivator and mediator of signal transduction by TGF-beta (transforming growth factor). Component of the heterotrimeric SMAD2/SMAD3-SMAD4 complex that forms in the nucleus and is required for the TGF-mediated signaling. Promotes binding of the SMAD2/SMAD4/FAST-1 complex to DNA and provides an activation function required for SMAD1 or SMAD2 to stimulate transcription. Component of the multimeric SMAD3/SMAD4/JUN/FOS complex which forms at the AP1 promoter site; required for syngernistic transcriptional activity in response to TGF-beta. May act as a tumor suppressor. -
Involvement in disease
Defects in SMAD4 are a cause of pancreatic cancer (PNCA) [MIM:260350].
Defects in SMAD4 are a cause of juvenile polyposis syndrome (JPS) [MIM:174900]; also known as juvenile intestinal polyposis (JIP). JPS is an autosomal dominant gastrointestinal hamartomatous polyposis syndrome in which patients are at risk for developing gastrointestinal cancers. The lesions are typified by a smooth histological appearance, predominant stroma, cystic spaces and lack of a smooth muscle core. Multiple juvenile polyps usually occur in a number of Mendelian disorders. Sometimes, these polyps occur without associated features as in JPS; here, polyps tend to occur in the large bowel and are associated with an increased risk of colon and other gastrointestinal cancers.
Defects in SMAD4 are a cause of juvenile polyposis/hereditary hemorrhagic telangiectasia syndrome (JP/HHT) [MIM:175050]. JP/HHT syndrome phenotype consists of the coexistence of juvenile polyposis (JIP) and hereditary hemorrhagic telangiectasia (HHT) [MIM:187300] in a single individual. JIP and HHT are autosomal dominant disorders with distinct and non-overlapping clinical features. The former, an inherited gastrointestinal malignancy predisposition, is caused by mutations in SMAD4 or BMPR1A, and the latter is a vascular malformation disorder caused by mutations in ENG or ACVRL1. All four genes encode proteins involved in the transforming-growth-factor-signaling pathway. Although there are reports of patients and families with phenotypes of both disorders combined, the genetic etiology of this association is unknown.
Defects in SMAD4 may be a cause of colorectal cancer (CRC) [MIM:114500]. -
Sequence similarities
Belongs to the dwarfin/SMAD family.
Contains 1 MH1 (MAD homology 1) domain.
Contains 1 MH2 (MAD homology 2) domain. -
Domain
The MH1 domain is required for DNA binding.
The MH2 domain is required for both homomeric and heteromeric interactions and for transcriptional regulation. Sufficient for nuclear import. -
Post-translational
modificationsMonoubiquitinated on Lys-519 by E3 ubiquitin-protein ligase TRIM33. Monoubiquitination hampers its ability to form a stable complex with activated SMAD2/3 resulting in inhibition of TGF-beta/BMP signaling cascade. Deubiqitination by USP9X restores its competence to mediate TGF-beta signaling. -
Cellular localization
Cytoplasm. Nucleus. Cytoplasmic in the absence of ligand. Migrates to the nucleus when complexed with R-SMAD. - Information by UniProt
-
Database links
- Entrez Gene: 540248 Cow
- Entrez Gene: 4089 Human
- Entrez Gene: 17128 Mouse
- Entrez Gene: 397142 Pig
- Entrez Gene: 50554 Rat
- Omim: 600993 Human
- SwissProt: Q1HE26 Cow
- SwissProt: Q13485 Human
see all -
Alternative names
- (Small) Mothers Against Decapentaplegic antibody
- Deleted in Pancreatic Carcinoma 4 antibody
- Deleted in Pancreatic Carcinoma antibody
see all
Images
-
All lanes : Anti-Smad4 antibody (ab236321) at 1/500 dilution
Lane 1 : SH-SY5Y (human neuroblastoma cell line from bone marrow) whole cell lysate
Lane 2 : NIH/3T3 (mouse embryo fibroblast cell line) whole cell lysate
Secondary
All lanes : Goat polyclonal to rabbit IgG at 1/10000 dilution
Predicted band size: 60 kDa -
Paraffin-embedded human kidney tissue stained for Smad4 using ab236321 at 1/100 dilution in immunohistochemical analysis.
-
Paraffin-embedded human colon cancer tissue stained for Smad4 using ab236321 at 1/100 dilution in immunohistochemical analysis.
-
Anti-Smad4 antibody (ab236321) at 1/500 dilution + HepG2 (human liver hepatocellular carcinoma cell line) whole cell lysate
Secondary
Goat polyclonal to rabbit IgG at 1/10000 dilution
Predicted band size: 60 kDa -
Smad4 was immunoprecipitated from 0.5 mg Jurkat (human T cell leukemia cell line from peripheral blood) whole cell lysate with ab236321.
Lane 1: Rabbit control IgG instead of ab236321 in Jurkat whole cell lysate.
Lane 2: ab236321 IP in Jurkat whole cell lysate.
Lane 3: Jurkat whole cell lysate 10 µg (Input).For western blotting, a HRP-conjugated Protein G antibody was used as the secondary antibody at 1/2000 dilution.
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
SDS download
-
Datasheet download
References (5)
ab236321 has been referenced in 5 publications.
- Shih CC et al. Protective Effects of One 2,4-Dihydro-3H-Pyrazol-3-one Derivative against Posterior Capsular Opacification by Regulation of TGF-β2/SMADs and Non-SMAD Signaling, Collagen I, and Fibronectin Proteins. Curr Issues Mol Biol 44:5048-5066 (2022). PubMed: 36286058
- Yang H et al. Berberine protects human and rat cardiomyocytes from hypoxia/reoxygenation-triggered apoptosis. Am J Transl Res 13:659-671 (2021). PubMed: 33594316
- Bonan NF et al. Inhibition of HGF/MET signaling decreases overall tumor burden and blocks malignant conversion in Tpl2-related skin cancer. Oncogenesis 8:1 (2019). PubMed: 30631034
- Stojnev S et al. Prognostic Impact of Canonical TGF-ß Signaling in Urothelial Bladder Cancer. Medicina (Kaunas) 55:N/A (2019). PubMed: 31238579
- Feng H et al. Overexpressed VEPH1 inhibits epithelial-mesenchymal transition, invasion, and migration of human cutaneous melanoma cells through inactivating the TGF-ß signaling pathway. Cell Cycle 18:2860-2875 (2019). PubMed: 31599708